Cargando…

Intrawound Vancomycin Powder for Spine Tumor Surgery

Study Design Retrospective evaluation of prospectively collected data. Objective To evaluate infection rates following intrawound vancomycin powder application during spine tumor surgery. Methods Patients ≥18 years old undergoing spine tumor surgery and receiving intrawound vancomycin powder at a si...

Descripción completa

Detalles Bibliográficos
Autores principales: Okafor, Richard, Molinari, William, Molinari, Robert, Mesfin, Addisu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836938/
https://www.ncbi.nlm.nih.gov/pubmed/27099810
http://dx.doi.org/10.1055/s-0035-1558655
_version_ 1782427789750697984
author Okafor, Richard
Molinari, William
Molinari, Robert
Mesfin, Addisu
author_facet Okafor, Richard
Molinari, William
Molinari, Robert
Mesfin, Addisu
author_sort Okafor, Richard
collection PubMed
description Study Design Retrospective evaluation of prospectively collected data. Objective To evaluate infection rates following intrawound vancomycin powder application during spine tumor surgery. Methods Patients ≥18 years old undergoing spine tumor surgery and receiving intrawound vancomycin powder at a single center between January 2008 and January 2015 were enrolled. Patient demographics (age, sex, body mass index [BMI]), tumor type (metastatic, primary) and location, surgical data (estimated blood loss [EBL], levels fused, type of decompression, length of surgery and hospitalization, discharge status from hospital), radiation therapy use, and infection rates (surgery to a minimum of 30 days postoperative) were evaluated. Results Forty patients (46 procedures) undergoing spine tumor surgery and intrawound vancomycin powder application were identified. Five were excluded because of death less than 30 days postoperatively, and 35 patients (41 procedures) were enrolled: 11 women and 24 men with an average age of 61.4 years (range 19 to 92) and average BMI of 27.3 (range 17.4 to 36.8). Three cases were primary spine tumors. Five were hematologic malignancies, and 27 were metastatic cancers. Twenty-one tumors were in the thoracic spine, 12 in the lumbar spine, and 8 in the cervical spine. Average EBL was 899 mL (range 25 to 3,500), average length of surgery was 241 minutes (range 78 to 495), and average hospital stay was 15.1 days (range 3 to 49). Two culture-proven infections (Staphylococcus aureus, Enterobacter cloacae) were noted in 41 procedures (4.9%). Ten patients (28.6%) had preoperative radiation only; 14 (40%) had postoperative radiation only, 5 (14.3%) had both preoperative and postoperative radiation, and 6 (17.1%) had no radiation. There were no associations between radiation treatment and postsurgical infections (p = 0.19). Conclusion In this first study evaluating intrawound vancomycin powder for spine tumor surgery, we report an infection rate of 4.9%. We found no correlations between radiation treatment and postsurgical infections.
format Online
Article
Text
id pubmed-4836938
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-48369382016-05-01 Intrawound Vancomycin Powder for Spine Tumor Surgery Okafor, Richard Molinari, William Molinari, Robert Mesfin, Addisu Global Spine J Article Study Design Retrospective evaluation of prospectively collected data. Objective To evaluate infection rates following intrawound vancomycin powder application during spine tumor surgery. Methods Patients ≥18 years old undergoing spine tumor surgery and receiving intrawound vancomycin powder at a single center between January 2008 and January 2015 were enrolled. Patient demographics (age, sex, body mass index [BMI]), tumor type (metastatic, primary) and location, surgical data (estimated blood loss [EBL], levels fused, type of decompression, length of surgery and hospitalization, discharge status from hospital), radiation therapy use, and infection rates (surgery to a minimum of 30 days postoperative) were evaluated. Results Forty patients (46 procedures) undergoing spine tumor surgery and intrawound vancomycin powder application were identified. Five were excluded because of death less than 30 days postoperatively, and 35 patients (41 procedures) were enrolled: 11 women and 24 men with an average age of 61.4 years (range 19 to 92) and average BMI of 27.3 (range 17.4 to 36.8). Three cases were primary spine tumors. Five were hematologic malignancies, and 27 were metastatic cancers. Twenty-one tumors were in the thoracic spine, 12 in the lumbar spine, and 8 in the cervical spine. Average EBL was 899 mL (range 25 to 3,500), average length of surgery was 241 minutes (range 78 to 495), and average hospital stay was 15.1 days (range 3 to 49). Two culture-proven infections (Staphylococcus aureus, Enterobacter cloacae) were noted in 41 procedures (4.9%). Ten patients (28.6%) had preoperative radiation only; 14 (40%) had postoperative radiation only, 5 (14.3%) had both preoperative and postoperative radiation, and 6 (17.1%) had no radiation. There were no associations between radiation treatment and postsurgical infections (p = 0.19). Conclusion In this first study evaluating intrawound vancomycin powder for spine tumor surgery, we report an infection rate of 4.9%. We found no correlations between radiation treatment and postsurgical infections. Georg Thieme Verlag KG 2015-07-16 2016-05 /pmc/articles/PMC4836938/ /pubmed/27099810 http://dx.doi.org/10.1055/s-0035-1558655 Text en © Thieme Medical Publishers
spellingShingle Article
Okafor, Richard
Molinari, William
Molinari, Robert
Mesfin, Addisu
Intrawound Vancomycin Powder for Spine Tumor Surgery
title Intrawound Vancomycin Powder for Spine Tumor Surgery
title_full Intrawound Vancomycin Powder for Spine Tumor Surgery
title_fullStr Intrawound Vancomycin Powder for Spine Tumor Surgery
title_full_unstemmed Intrawound Vancomycin Powder for Spine Tumor Surgery
title_short Intrawound Vancomycin Powder for Spine Tumor Surgery
title_sort intrawound vancomycin powder for spine tumor surgery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836938/
https://www.ncbi.nlm.nih.gov/pubmed/27099810
http://dx.doi.org/10.1055/s-0035-1558655
work_keys_str_mv AT okaforrichard intrawoundvancomycinpowderforspinetumorsurgery
AT molinariwilliam intrawoundvancomycinpowderforspinetumorsurgery
AT molinarirobert intrawoundvancomycinpowderforspinetumorsurgery
AT mesfinaddisu intrawoundvancomycinpowderforspinetumorsurgery